Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

MTEM

Molecular Templates Inc

Nov 20 • 04:00PM ET

0.3880

Dollar change -0.0157
Percentage change -3.89	%

Healthcare • Biotechnology • USA • NASD

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-2.70	Insider Own	17.39%	Shs Outstand	6.58M	Perf Week	20.46%
Market Cap	2.55M	Forward P/E	-	EPS next Y	-	Insider Trans	-52.76%	Shs Float	5.44M	Perf Month	-45.11%
Income	-15.63M	PEG	-	EPS next Q	-	Inst Own	41.02%	Short Float	4.97%	Perf Quarter	-73.78%
Sales	25.47M	P/S	0.10	EPS this Y	-	Inst Trans	-8.73%	Short Ratio	0.03	Perf Half Y	-71.47%
Book/sh	1.08	P/B	0.36	EPS next Y	-	ROA	-50.24%	Short Interest	0.27M	Perf Year	-91.95%
Cash/sh	1.47	P/C	0.26	EPS next 5Y	3.20%	ROE	-929.14%	52W Range	0.29 - 5.37	Perf YTD	-89.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	34.83%	ROI	-100.81%	52W High	-92.77%	Beta	1.12
Dividend TTM	-	Quick Ratio	1.56	Sales past 5Y	59.75%	Gross Margin	80.33%	52W Low	31.53%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	1.56	EPS Y/Y TTM	78.46%	Oper. Margin	-74.02%	RSI (14)	39.28	Volatility	70.01% 23.05%
Employees	62	Debt/Eq	1.55	Sales Y/Y TTM	-49.41%	Profit Margin	-61.35%	Recom	1.00	Target Price	18.00
Option/Short	No / Yes	LT Debt/Eq	1.18	EPS Q/Q	57.32%	Payout	-	Rel Volume	0.08	Prev Close	0.40
Sales Surprise	33.02%	EPS Surprise	14.58%	Sales Q/Q	-91.67%	Earnings	Aug 14 AMC	Avg Volume	9.62M	Price	0.39
SMA20	-12.83%	SMA50	-55.55%	SMA200	-76.03%	Trades		Volume	831,343	Change	-3.89%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-21-21	Initiated	BofA Securities	Buy	$12
Feb-01-21	Initiated	UBS	Neutral	$13
Sep-08-20	Initiated	Jefferies	Buy	$21
Mar-25-20	Initiated	Stifel	Buy	$19
Feb-27-20	Initiated	Barclays	Overweight	$22
Apr-29-19	Initiated	UBS	Buy	$12
Dec-11-18	Initiated	Oppenheimer	Outperform	$15
Oct-08-18	Initiated	Laidlaw	Buy	$18

Aug-14-24 04:21PM	Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update (GlobeNewswire) -6.24%
Jun-21-24 07:30AM	7 F-Rated Penny Stocks to Avoid This June (InvestorPlace) -8.40%
Jun-03-24 08:11AM	Molecular Templates, Inc. Provides Interim Update (GlobeNewswire) +10.66%
May-30-24 07:47AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +5.17%
May-15-24 11:53PM	MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:11PM	Loading…
05:11PM	Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Apr-11-24 01:52PM	MTEM Stock Earnings: Molecular Templates Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
Apr-09-24 08:11AM	Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism (GlobeNewswire) -6.57%
Mar-29-24 08:21AM	Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Mar-28-24 08:11AM	Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement (GlobeNewswire) -5.08%
Mar-04-24 08:11AM	Molecular Templates, Inc. Provides Interim Update (GlobeNewswire)
Feb-08-24 05:55PM	Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Nov-13-23 04:11PM	Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Nov-02-23 04:11PM	Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors (GlobeNewswire)
Nov-01-23 04:12PM	Molecular Templates to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.09%
04:11PM	Loading…
Sep-28-23 04:11PM	Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer (GlobeNewswire)
Aug-25-23 08:50AM	Looking for a Fast-paced Momentum Stock at a Bargain? Consider Molecular Templates Inc. (MTEM) (Zacks)
Aug-11-23 11:22AM	Molecular Templates Announces 1-for-15 Reverse Stock Split (GlobeNewswire)
Aug-10-23 08:08AM	Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Aug-04-23 09:16AM	After layoffs, Molecular Templates overhauls C-suite (American City Business Journals)
Aug-02-23 04:11PM	Molecular Templates Announces Executive Leadership Changes (GlobeNewswire)
Jul-20-23 06:55AM	Daily Vickers Top Buyers & Sellers for 07/20/2023 (Argus Research)
Jul-13-23 08:14AM	Molecular Templates Announces Up to $40 Million Private Placement Offering (GlobeNewswire) +8.51%
Jun-16-23 08:56PM	Molecular Templates Announces Debt Payoff and Restructuring (GlobeNewswire) +6.02%
Jun-01-23 07:57AM	Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma (GlobeNewswire)
May-26-23 05:10PM	Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-15-23 04:13PM	Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update (GlobeNewswire) +9.50%
May-04-23 10:00AM	Will Molecular Templates Inc. (MTEM) Report Negative Q1 Earnings? What You Should Know (Zacks) +8.86%
Apr-17-23 08:00AM	Improved Revenues Required Before Molecular Templates, Inc. (NASDAQ:MTEM) Stock's 45% Jump Looks Justified (Simply Wall St.)
Apr-07-23 06:50PM	Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169 (GlobeNewswire)
07:25PM	Loading…
Mar-30-23 07:25PM	Molecular Templates Inc. (MTEM) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +8.51%
06:10PM	Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Mar-09-23 10:02AM	Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4 (GlobeNewswire) +5.98%
Mar-01-23 04:44PM	Molecular Templates Announces Participation in Upcoming Conferences (GlobeNewswire)
Dec-02-22 05:02PM	Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -6.13%
Nov-23-22 04:30PM	Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISIs 5th Annual HealthCONx Conference and Piper Sandlers 34th Annual Healthcare Conference (GlobeNewswire)
Nov-13-22 07:39AM	Molecular Templates Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-10-22 05:55PM	Molecular Templates Inc. (MTEM) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +7.16%
04:15PM	Molecular Templates, Inc. Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-04-22 11:00AM	Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
Aug-31-22 04:52PM	Molecular Templates Announces Participation in Four Upcoming Conferences (GlobeNewswire)
Aug-17-22 06:17AM	Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2022 (Simply Wall St.)
Aug-11-22 04:10PM	Molecular Templates, Inc. Reports Second Quarter 2022 Financial Results (GlobeNewswire) +6.64%
Aug-08-22 10:00AM	Field Trip Health Ltd. (FTRP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Aug-04-22 10:00AM	Molecular Templates Inc. (MTEM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jun-06-22 08:00AM	Molecular Templates Presentations at the 2022 ASCO Annual Meeting Demonstrate Advancement in PD-L1 and HER2 Programs (GlobeNewswire) -5.01%
May-17-22 04:05PM	Molecular Templates to Present at Upcoming Investor Conferences (GlobeNewswire) -6.84%
May-12-22 04:30PM	Molecular Templates, Inc. Reports First Quarter 2022 Financial Results (GlobeNewswire) +5.08%
May-10-22 05:25PM	Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings and Revenue Estimates (Zacks) +8.21% -17.24%
May-06-22 10:18AM	Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt (Simply Wall St.) -8.23%
May-05-22 05:55PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -8.14%
03:00PM	Will Molecular Templates Inc. (MTEM) Report Negative Q1 Earnings? What You Should Know (Zacks)
May-04-22 07:25AM	Amneal Pharmaceuticals (AMRX) Q1 Earnings Meet Estimates (Zacks)
Apr-12-22 07:30AM	Molecular Templates Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2022 Highlight Potential of ETB Approach (GlobeNewswire)
Apr-08-22 08:00AM	Molecular Templates to Host Webinar on a Unique Approach to Immuno-Oncology for Solid Tumors (GlobeNewswire) -5.18%
Mar-28-22 04:30PM	Molecular Templates, Inc. Reports Fourth Quarter 2021 Financial Results (GlobeNewswire) +21.11%
Mar-18-22 12:39PM	Investors in Molecular Templates (NASDAQ:MTEM) have unfortunately lost 77% over the last year (Simply Wall St.)
Mar-02-22 08:00AM	Molecular Templates Strengthens Board of Directors and Management Team (GlobeNewswire)
Mar-01-22 08:00AM	Molecular Templates to Present at the Upcoming Investor Conferences (GlobeNewswire)
Jan-17-22 07:08AM	Is Molecular Templates, Inc. (NASDAQ:MTEM) Popular Amongst Institutions? (Simply Wall St.)
Nov-30-21 05:30PM	Molecular Templates Provides Corporate Update and Outlines 2022 Milestones (GlobeNewswire)
Nov-18-21 08:00AM	Molecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402 (GlobeNewswire) -5.08%
Nov-16-21 09:06AM	Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way? (Simply Wall St.) -7.06%
Nov-15-21 12:25PM	Molecular Templates Inc. (MTEM) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Molecular Templates, Inc. Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Oct-28-21 03:05PM	Molecular Templates Inc. (MTEM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
12:31PM	Zacks Industry Outlook Highlights: Xencor, Enanta, Catalyst Pharmaceuticals, and Molecular Templates (Zacks)
Oct-12-21 09:08AM	Wall Street Analysts Predict a 98% Upside in Molecular Templates Inc. (MTEM): Here's What You Should Know (Zacks)
Sep-22-21 03:24AM	Molecular Templates Inc. (MTEM) Moves 11.8% Higher: Will This Strength Last? (Zacks)
Sep-20-21 08:00AM	Molecular Templates to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (GlobeNewswire)
Sep-14-21 12:09PM	2 Strong Buy Stocks Trading at Steep Discounts (TipRanks)
Aug-12-21 08:05PM	Molecular Templates Inc. (MTEM) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +9.99%
04:30PM	Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results (GlobeNewswire)
Aug-05-21 10:50AM	10 Best Biotech Stocks to Buy According to Alan Fraziers Frazier Healthcare Partners (Insider Monkey)
Jul-29-21 03:05PM	Molecular Templates Inc. (MTEM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jul-21-21 03:20PM	Molecular Templates, Inc. (MTEM) Fell Out Of Favor With Hedge Funds? (Insider Monkey)
Jul-19-21 05:27AM	Here's What Molecular Templates, Inc.'s (NASDAQ:MTEM) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jul-09-21 08:00AM	Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors (GlobeNewswire)
Jul-06-21 08:00AM	Molecular Templates to Present at the Ladenburg Thalmann 2021 Healthcare Conference (GlobeNewswire)
Jun-30-21 08:30AM	Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors (GlobeNewswire)
May-18-21 03:04AM	Analysts Are More Bearish On Molecular Templates, Inc. (NASDAQ:MTEM) Than They Used To Be (Simply Wall St.)
May-13-21 07:50PM	Molecular Templates Inc. (MTEM) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -5.76%
04:30PM	Molecular Templates, Inc. Reports First Quarter 2021 Financial Results (GlobeNewswire)
Apr-20-21 11:36AM	Insider Buying Of Molecular Templates Stock Corresponds With Analyst Ratings (SmarterAnalyst)
Apr-12-21 07:00AM	Molecular Templates Announces Poster Presentations on its Engineered Toxin Bodies at the American Association of Cancer Research (AACR) Virtual Annual Meeting I (GlobeNewswire)
Apr-05-21 04:12PM	Why Molecular Templates Stock Crashed Today (Motley Fool) -23.55% -9.52%
11:48AM	Molecular Templates Stock Falls After It Stops MT-3724 Development In Hematological Malignancies (Benzinga)
07:00AM	Molecular Templates to Prioritize Next-Generation ETB Candidates (GlobeNewswire)
Mar-21-21 03:37AM	Upgrade: Analysts Just Made A Dazzling Increase To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts (Simply Wall St.)
Mar-18-21 04:30PM	Molecular Templates, Inc. Reports Fourth Quarter 2020 Financial Results (GlobeNewswire) +7.81%
Feb-26-21 08:00AM	Molecular Templates to Participate in Upcoming Virtual Investor Conferences (GlobeNewswire)
Feb-21-21 03:02AM	Newsflash: Molecular Templates, Inc. (NASDAQ:MTEM) Analysts Have Been Trimming Their Revenue Forecasts (Simply Wall St.)
Feb-18-21 07:30AM	Molecular Templates, Inc. Announces Pricing of $75.9 Million Public Equity Offering (GlobeNewswire) -7.49%
Feb-17-21 04:05PM	Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-11-21 09:13AM	Molecular Templates Shares Jump On Research Pact With Bristol-Myers In Cancer Settings (Benzinga) +8.74%
07:30AM	Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer (GlobeNewswire)
Feb-08-21 06:20AM	Investors Who Bought Molecular Templates (NASDAQ:MTEM) Shares Three Years Ago Are Now Up 41% (Simply Wall St.)
Jan-19-21 08:00AM	Molecular Templates Announces FDA Acceptance of IND Application for MT-6402, a PD-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology (GlobeNewswire) +6.70%
Dec-21-20 04:30PM	Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study (GlobeNewswire) +11.89%
Dec-18-20 10:21PM	Is MTEM A Good Stock To Buy Now According To Hedge Funds? (Insider Monkey)

Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariepy, and Leigh Revers in 2001 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIOTECH TARGET N V	10% Owner	Nov 14 '24	Sale	0.66	1,279,820	845,833	0	Nov 18 09:12 PM
BIOTECH TARGET N V	10% Owner	Apr 02 '24	Buy	2.35	250,000	587,500	1,279,820	Apr 04 08:13 PM

Open in Screener

MGNX

Macrogenics Inc

Nov 20 • 04:00PM ET

3.28

Dollar change -0.20
Percentage change -5.75	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD MRNA ALNY EXEL BGNE AGEN INCY ZLAB UBX DLTH

| Held by: VTI IWM VXF IWO IBB SCHA VTWO VHT IWC DFAC

Index	RUT	P/E	-	EPS (ttm)	-1.57	Insider Own	7.51%	Shs Outstand	62.07M	Perf Week	-13.00%
Market Cap	205.86M	Forward P/E	-	EPS next Y	-2.22	Insider Trans	0.00%	Shs Float	58.05M	Perf Month	-15.90%
Income	-97.62M	PEG	-	EPS next Q	-0.40	Inst Own	84.40%	Short Float	9.40%	Perf Quarter	-1.50%
Sales	141.33M	P/S	1.46	EPS this Y	-729.52%	Inst Trans	-6.26%	Short Ratio	8.33	Perf Half Y	-30.21%
Book/sh	1.91	P/B	1.71	EPS next Y	-78.13%	ROA	-32.30%	Short Interest	5.46M	Perf Year	-57.01%
Cash/sh	3.19	P/C	1.03	EPS next 5Y	-	ROE	-62.17%	52W Range	2.95 - 21.88	Perf YTD	-65.90%
Dividend Est.	-	P/FCF	-	EPS past 5Y	48.88%	ROI	-65.33%	52W High	-85.01%	Beta	2.04
Dividend TTM	-	Quick Ratio	3.69	Sales past 5Y	15.77%	Gross Margin	89.84%	52W Low	11.14%	ATR (14)	0.32
Dividend Ex-Date	-	Current Ratio	3.75	EPS Y/Y TTM	-295.28%	Oper. Margin	-75.78%	RSI (14)	38.09	Volatility	7.15% 9.05%
Employees	339	Debt/Eq	0.28	Sales Y/Y TTM	16.68%	Profit Margin	-69.07%	Recom	2.36	Target Price	7.29
Option/Short	Yes / Yes	LT Debt/Eq	0.24	EPS Q/Q	218.23%	Payout	-	Rel Volume	1.00	Prev Close	3.48
Sales Surprise	26.37%	EPS Surprise	325.53%	Sales Q/Q	964.81%	Earnings	Nov 05 AMC	Avg Volume	655.15K	Price	3.28
SMA20	-12.84%	SMA50	-10.34%	SMA200	-59.49%	Trades		Volume	658,172	Change	-5.75%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-07-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-01-24	Downgrade	BTIG Research	Buy → Neutral
Jul-31-24	Downgrade	Guggenheim	Buy → Neutral
Jul-31-24	Downgrade	B. Riley Securities	Buy → Neutral	$18 → $5
May-10-24	Downgrade	TD Cowen	Buy → Hold
May-10-24	Downgrade	Stifel	Buy → Hold	$29 → $7
May-10-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$24 → $8
Apr-26-24	Initiated	B. Riley Securities	Buy	$25
Apr-09-24	Upgrade	TD Cowen	Hold → Buy
Mar-04-24	Reiterated	BTIG Research	Buy	$12 → $24
Feb-14-24	Downgrade	H.C. Wainwright	Buy → Neutral	$12 → $14
Dec-20-23	Upgrade	Citigroup	Neutral → Buy	$7 → $13
Nov-07-23	Upgrade	Guggenheim	Neutral → Buy	$12
Mar-17-23	Downgrade	Guggenheim	Buy → Neutral
Nov-22-22	Downgrade	Cowen	Outperform → Market Perform
Nov-14-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$5.70 → $16
Jul-18-22	Downgrade	SMBC Nikko	Outperform → Neutral	$5
Jul-11-22	Downgrade	BMO Capital Markets	Outperform → Market Perform	$31 → $4
May-04-22	Downgrade	Guggenheim	Buy → Neutral
Feb-28-22	Upgrade	Citigroup	Neutral → Buy	$23 → $21

Show Previous Ratings

Nov-06-24 04:30PM	MacroGenics to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.14% +6.44%
08:51AM	Q3 2024 MacroGenics Inc Earnings Call (Thomson Reuters StreetEvents)
02:25AM	Macrogenics Inc (MGNX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Developments (GuruFocus.com)
Nov-05-24 10:15PM	MacroGenics (MGNX) Q3 2024 Earnings Call Transcript (Motley Fool)
08:00PM	Here's What Key Metrics Tell Us About MacroGenics (MGNX) Q3 Earnings (Zacks)
07:30PM	Loading…
07:30PM	MacroGenics (MGNX) Beats Q3 Earnings and Revenue Estimates (Zacks)
06:26PM	MacroGenics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-04-24 07:13AM	Earnings To Watch: Macrogenics Inc (MGNX) Reports Q3 2024 Result (GuruFocus.com)
Oct-30-24 07:30AM	MacroGenics Announces Leadership Transition (GlobeNewswire)
Oct-29-24 04:30PM	MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call (GlobeNewswire) -5.11%
Oct-23-24 08:41AM	TerSera acquires global rights to MacroGenics' MARGENZA for breast cancer treatment (Pharmaceutical Business Review)
Oct-22-24 07:30AM	MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA (Business Wire)
Sep-24-24 05:45AM	MacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGNX (PR Newswire)
Sep-23-24 11:05AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile) -6.71%
05:06AM	Loading…
Sep-20-24 05:06AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Sep-19-24 01:29PM	MacroGenics, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights MGNX (GlobeNewswire)
Sep-17-24 08:30AM	MacroGenics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MGNX (PR Newswire)
05:45AM	Investors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX (PR Newswire)
Sep-15-24 03:00AM	MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024 (GlobeNewswire)
Sep-13-24 08:34AM	Do Options Traders Know Something About MacroGenics (MGNX) Stock We Don't? (Zacks)
Sep-11-24 08:30AM	MacroGenics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MGNX (PR Newswire)
Sep-08-24 07:10PM	MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024 (GlobeNewswire)
Sep-04-24 03:29PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Sep-03-24 05:45AM	Investors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX (PR Newswire) -6.55%
Sep-02-24 02:05PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial Hagens Berman (GlobeNewswire)
Aug-30-24 09:43AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Aug-29-24 01:09PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial Hagens Berman (GlobeNewswire)
Aug-27-24 10:48AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Aug-26-24 03:40PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial Hagens Berman (GlobeNewswire)
03:16PM	Loading…
Aug-22-24 03:16PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial Hagens Berman (GlobeNewswire) -7.50%
01:17PM	MacroGenics, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights MGNX (GlobeNewswire)
Aug-21-24 07:05AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Aug-19-24 04:37PM	MacroGenics (MGNX) Under Fire as Analyst Downgrade Deepens Crisis Hagens Berman (GlobeNewswire) +9.91%
Aug-17-24 03:29PM	Kessler Topaz Meltzer & Check, LLP Encourages MacroGenics, Inc. Investors with Losses to Contact the Firm (GlobeNewswire)
Aug-16-24 05:45AM	MacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGNX (PR Newswire)
04:26AM	MacroGenics (MGNX) Under Fire as Analyst Downgrade Deepens Crisis - Hagens Berman (Newsfile)
Aug-15-24 02:19PM	MacroGenics (MGNX) Under Fire as Analyst Downgrade Deepens Crisis Hagens Berman (GlobeNewswire)
Aug-14-24 12:19PM	MacroGenics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights MGNX (GlobeNewswire) -5.38%
Aug-13-24 02:31PM	MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor Suit - Hagens Berman (Newsfile) +5.37%
12:45AM	MGNX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case (GlobeNewswire)
Aug-12-24 10:20AM	MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor Suit Hagens Berman (GlobeNewswire)
Aug-08-24 11:31AM	MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor Suit Hagens Berman (GlobeNewswire)
Aug-07-24 08:53AM	MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor Suit - Hagens Berman (Newsfile) -7.14%
Aug-06-24 09:30PM	Compared to Estimates, MacroGenics (MGNX) Q2 Earnings: A Look at Key Metrics (Zacks)
05:30PM	MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:33PM	MacroGenics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-30-24 04:10PM	MacroGenics Provides Vobramitamab Duocarmazine Update (GlobeNewswire) -28.38%
04:01PM	MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte (GlobeNewswire)
Jul-24-24 01:29PM	MacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash Hagens Berman (GlobeNewswire)
Jul-16-24 03:57PM	MacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash Hagens Berman (GlobeNewswire) +11.49%
Jul-10-24 05:19PM	MacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash Hagens Berman (GlobeNewswire) +8.90%
Jul-03-24 05:34PM	MacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash Hagens Berman (GlobeNewswire)
Jun-20-24 01:28PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire)
Jun-13-24 12:29PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire) -6.21%
Jun-11-24 07:45AM	MacroGenics to Participate in Upcoming Investor Conference (GlobeNewswire) +7.64%
May-29-24 12:44PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire)
May-25-24 12:00PM	3 Biotech Stocks That Could Be Millionaire-Makers: May Edition (InvestorPlace)
May-17-24 12:50PM	Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment (PR Newswire) -14.75%
May-16-24 12:59PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire) +8.70%
May-13-24 12:30PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire) +32.33%
07:30AM	MacroGenics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-10-24 06:01PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire) -77.44%
04:51PM	Macrogenics Stock Drops 77% After Study Deaths (The Wall Street Journal)
03:29PM	Macrogenics Inc (MGNX) Q1 2024 Earnings: Misses Revenue Estimates Amidst Ongoing Clinical ... (GuruFocus.com)
03:17PM	MacroGenics, Inc. (NASDAQ:MGNX) Q1 2024 Earnings Call Transcript (Insider Monkey)
02:01PM	Top Midday Decliners (MT Newswires)
08:35AM	Why Is Macrogenics (MGNX) Stock Down 69% Today? (InvestorPlace)
07:48AM	Top Premarket Decliners (MT Newswires)
07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
07:15AM	BMO Downgrades MacroGenics to Market Perform From Outperform, Price Target at $8 (MT Newswires)
07:14AM	Stifel Downgrades MacroGenics to Hold (MT Newswires)
07:12AM	TD Cowen Downgrades MacroGenics to Hold From Buy (MT Newswires)
07:12AM	MacroGenics Says Five Patients Died in Cancer Study (MT Newswires)
06:02AM	MacroGenics' stock crashes after 5 deaths seen in ADC trial (FierceBiotech.com)
04:57AM	MacroGenics Q1 Loss Widens, Revenue Falls (MT Newswires)
02:15AM	MacroGenics (MGNX) Q1 2024 Earnings Call Transcript (Motley Fool)
May-09-24 08:57PM	MGNX Stock Earnings: Macrogenics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:10PM	MacroGenics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data (GlobeNewswire)
May-03-24 07:30AM	MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call (GlobeNewswire)
May-01-24 10:05AM	Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 (PR Newswire) +5.21%
Apr-26-24 08:00AM	B. Riley Securities Initiates MacroGenics With Buy Rating, $25 Price Target (MT Newswires)
Apr-03-24 04:30PM	MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures (GlobeNewswire) +30.07%
Mar-14-24 08:18AM	MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-08-24 07:19AM	Q4 2023 MacroGenics Inc Earnings Call (Thomson Reuters StreetEvents) -15.02%
12:30AM	MacroGenics (MGNX) Q4 2023 Earnings Call Transcript (Motley Fool)
Mar-07-24 10:42PM	Macrogenics Inc (MGNX) Reports Strong Financial Position and Advancements in Cancer Treatment ... (GuruFocus.com)
09:55PM	MGNX Stock Earnings: Macrogenics Misses EPS for Q4 2023 (InvestorPlace)
05:30PM	MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:01PM	MacroGenics Provides Update on Corporate Progress and 2023 Financial Results (GlobeNewswire)
Mar-06-24 11:29PM	Insider Sell: COO Eric Risser Sells 41,159 Shares of Macrogenics Inc (MGNX) (GuruFocus.com)
Mar-01-24 05:48PM	MacroGenics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.24% +8.71%
Feb-29-24 10:00AM	Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-27-24 05:45PM	MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call (GlobeNewswire)
Feb-02-24 04:30PM	MacroGenics to Participate in Upcoming Investor Conference (GlobeNewswire) +8.45%
07:19AM	MacroGenics (MGNX) Surges 6.8%: Is This an Indication of Further Gains? (Zacks)
Jan-15-24 04:51PM	The 3 Most Undervalued Biotech Stocks to Buy in January (InvestorPlace)

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SIEGEL JAY PHILIP	Director	May 20 '24	Option Exercise	0.00	4,500	0	4,500	May 22 04:34 PM
HEIDEN WILLIAM K	Director	May 20 '24	Option Exercise	0.00	4,500	0	4,500	May 22 04:34 PM
Jackson Scott Thomas	Director	May 20 '24	Option Exercise	0.00	4,500	0	4,500	May 22 04:34 PM
STUMP DAVID C	Director	May 20 '24	Option Exercise	0.00	4,500	0	4,500	May 22 04:33 PM
O'Brien Federica F.	Director	May 20 '24	Option Exercise	0.00	4,500	0	4,500	May 22 04:33 PM
Liu Margaret	Director	May 20 '24	Option Exercise	0.00	4,500	0	4,500	May 22 04:33 PM
Chhabra Meenu	Director	May 20 '24	Option Exercise	0.00	4,500	0	4,500	May 22 04:33 PM
Ferrante Karen Jean	Director	May 20 '24	Option Exercise	0.00	4,500	0	4,500	May 22 04:32 PM
HURWITZ EDWARD	Director	May 20 '24	Option Exercise	0.00	4,500	0	37,574	May 22 04:32 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Apr 04 '24	Option Exercise	4.82	42,500	204,850	51,395	Apr 08 06:07 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Apr 04 '24	Sale	15.55	51,395	799,148	0	Apr 08 06:07 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Mar 06 '24	Option Exercise	10.90	19,625	213,875	28,520	Mar 08 04:14 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Mar 06 '24	Sale	21.50	19,625	421,938	8,895	Mar 08 04:14 PM
Risser Eric Blasius	Chief Operating Officer	Mar 04 '24	Option Exercise	10.15	15,000	152,250	80,059	Mar 06 04:20 PM
Risser Eric Blasius	Chief Operating Officer	Mar 04 '24	Sale	19.76	41,159	813,501	38,900	Mar 06 04:20 PM
Spitznagel Thomas	Sr VP, Technical Ops	Mar 04 '24	Option Exercise	11.50	10,000	115,000	18,316	Mar 06 04:19 PM
Spitznagel Thomas	Sr VP, Technical Ops	Mar 04 '24	Sale	20.00	10,000	200,000	8,316	Mar 06 04:19 PM
Karrels James	SVP, CFO and Secretary	Mar 04 '24	Sale	20.50	30,000	615,000	171,452	Mar 06 04:18 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Feb 26 '24	Sale	17.22	16,124	277,655	8,895	Feb 28 04:20 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Feb 22 '24	Option Exercise	0.00	26,250	0	35,145	Feb 26 04:27 PM
Bonvini Ezio	Sr VP, Research & CSO	Feb 22 '24	Option Exercise	0.00	28,125	0	110,258	Feb 26 04:26 PM
Eck Stephen L.	Chief Medical Officer	Feb 15 '24	Option Exercise	0.00	16,670	0	16,670	Feb 20 06:41 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Feb 15 '24	Option Exercise	0.00	13,336	0	13,336	Feb 20 06:05 PM
Koenig Scott	President and CEO	Feb 15 '24	Option Exercise	0.00	42,341	0	1,091,977	Feb 20 06:04 PM
Cilinski Lynn	VP, Controller and Treasurer	Feb 15 '24	Option Exercise	0.00	6,668	0	8,591	Feb 20 06:04 PM
Risser Eric Blasius	Chief Operating Officer	Feb 15 '24	Option Exercise	0.00	16,670	0	70,938	Feb 20 06:04 PM
Karrels James	SVP, CFO and Secretary	Feb 15 '24	Option Exercise	0.00	15,003	0	206,779	Feb 20 06:04 PM
Spitznagel Thomas	Sr VP, Technical Ops	Feb 15 '24	Option Exercise	0.00	13,336	0	13,336	Feb 20 06:03 PM
Bonvini Ezio	Sr VP, Research & CSO	Feb 15 '24	Option Exercise	0.00	16,670	0	88,004	Feb 20 06:03 PM
Bonvini Ezio	Sr VP, Research & CSO	Feb 07 '24	Sale	18.00	3,334	60,012	71,334	Feb 07 04:19 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Feb 05 '24	Option Exercise	11.11	76,251	847,355	76,251	Feb 07 04:17 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Feb 05 '24	Sale	16.50	76,251	1,258,142	0	Feb 07 04:17 PM
Bonvini Ezio	Sr VP, Research & CSO	Feb 01 '24	Sale	15.00	13,316	199,740	74,668	Feb 02 04:21 PM
Bonvini Ezio	Sr VP, Research & CSO	Jan 19 '24	Sale	12.00	13,316	159,792	87,984	Jan 22 04:57 PM
Bonvini Ezio	Sr VP, Research & CSO	Dec 20 '23	Sale	10.08	18,880	190,310	101,300	Dec 21 04:12 PM

MTEM

Molecular Templates Inc

MGNX

Macrogenics Inc

Upgrade your FINVIZ experience